The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Emerging CAR-T therapies for T-cell lymphoma
Emmanuel Bachy, MD, PhD, Lyon Sud Hospital Center, Lyon, France, outlines novel promising CAR-T therapies in development for the treatment of T-cell lymphoma, including a CAR-T directed against the constant fraction of the T-cell receptor (TCR) and an allogeneic product directed against CD70. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
